Is Screening for Hepatitis B and Hepatitis C Useful in Patients with Recent-Onset Polyarthritis? The ESPOIR Cohort Study
暂无分享,去创建一个
M. Dougados | J. Daurès | A. Saraux | V. Devauchelle-Pensec | S. Jousse-Joulin | X. Guennoc | V. Narbonne
[1] D. Vassilopoulos,et al. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations , 2008, Arthritis research & therapy.
[2] M. Dougados,et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. , 2007, Joint, bone, spine : revue du rhumatisme.
[3] C. Derancourt,et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low‐grade cutaneous B‐cell lymphoma , 2006, The British journal of dermatology.
[4] F. Guillemin,et al. TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. , 2006, Joint, bone, spine : revue du rhumatisme.
[5] M. Dougados,et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.
[6] M. Dougados,et al. Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. , 2006, Joint, bone, spine : revue du rhumatisme.
[7] M. Erman,et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. , 2006, Clinical and laboratory haematology.
[8] F. Guillemin,et al. Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis. , 2006, The Journal of rheumatology.
[9] J. Zarski. Épidémiologie de l’hépatite chronique B , 2006 .
[10] S. Pol,et al. Hepatitis B virus genotypes and extrahepatic manifestations. , 2005, Journal of hepatology.
[11] M. Dougados,et al. Usefulness of routine hepatitis C virus, hepatitis B virus, and parvovirus B19 serology in the diagnosis of recent-onset inflammatory arthritides. , 2005, Arthritis and rheumatism.
[12] M. Asaka,et al. Reactivation of hepatitis B virus with rituximab , 2005, Expert opinion on drug safety.
[13] R. Martins,et al. Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[14] F. Guillemin,et al. Costs of workups for the diagnosis of early arthritis: results of a nationwide survey. , 2004, Arthritis and rheumatism.
[15] M. Kurosaki,et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. , 2004, Clinical and experimental rheumatology.
[16] L. Punzi,et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate , 2003, Annals of the rheumatic diseases.
[17] E. Boyko,et al. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. , 2003, The Journal of rheumatology.
[18] M. Dougados,et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.
[19] F. Roudot-Thoraval. Épidémiologie de l’hépatite C , 2002 .
[20] A. Murasawa,et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. , 2001, Arthritis and rheumatism.
[21] J. Rivera,et al. Arthritis in patients with chronic hepatitis C virus infection. , 1999, The Journal of rheumatology.
[22] P. Davis. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. , 1998 .
[23] J. Pawlotsky,et al. Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: A French survey of 6,664 patients , 1997, Hepatology.
[24] J. Desenclos,et al. Hepatitis C in a French population‐based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors , 1997, Hepatology.
[25] D. Scott,et al. Classification and epidemiology of systemic vasculitis. , 1994, British journal of rheumatology.
[26] J. Winfield,et al. Arthritis artefacta: factitious disease in rheumatology. , 1991, British journal of rheumatology.
[27] M. Sherman,et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. , 1990, Annals of internal medicine.
[28] J. Zarski. [Epidemiology of chronic hepatitis B]. , 2006, Presse medicale.
[29] J. Pawlotsky,et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. , 2004, The Journal of rheumatology.
[30] J. Narváez,et al. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. , 1998, The Journal of rheumatology.
[31] C. Vitali,et al. Anti-hepatitis C virus antibodies in primary Sjögren's syndrome: false positive results are related to hyper-gamma-globulinaemia. , 1992, Clinical and experimental rheumatology.